

May 12, 2017



DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

**More successful NDA approvals
than any other. Delivered.**



Patheon
A HEALTHIER WORLD. DELIVERED.

1. [Avantor to Acquire VWR for \\$6.4 Billion](#)

Avantor, a supplier of ultra-high-purity materials for the life sciences and advanced technology industries, has agreed to acquire VWR, a provider of product, supply chain, and service solutions to laboratory and production customers, for \$6.4 billion. [Read More](#)

2. [US Senate Confirms Scott Gottlieb as Next FDA Commissioner](#)

The US Senate has confirmed the nomination of Scott Gottlieb, MD, as the next Commissioner of the US Food and Drug Administration. He formerly served as Deputy Commissioner for Medical and Scientific Affairs for the FDA and most recently was a partner in a private-equity firm. [Read More](#)

3. [Patheon Completes \\$26 Million Sterile Manufacturing Expansion](#)

Patheon has completed a \$26-million expansion project at its Greenville, North Carolina manufacturing site that updates one of its sterile Pharmaceutical Development Services (PDS) suites and adds a sterile PDS suite to provide 7,000-square-feet in GMP sterile manufacturing space. [Read More](#)

4. [Teva To Sell Women's Health and European Oncology & Pain Businesses](#)

Teva Pharmaceutical Industries plans to sell certain non-core assets, including its global women's health business and its oncology and pain business in Europe, to pay down debt. The company made the announcement as part of its first-quarter earnings report. [Read More](#)

5. [Lonza Receives FDA Warning Letter for Bioscience Facility](#)

Lonza has received a FDA Warning Letter for its facility in Walkersville, Maryland, relating to various technical issues for validation and aseptic process simulation. The facility supports the company's bioscience business. [Read More](#)

6. [AstraZeneca Has Late-Stage Setback for Asthma Drug](#)

AstraZeneca reports that tralokinumab, an anti-interleukin-13 human monoclonal antibody for treating severe, uncontrolled asthma, did not meet its primary endpoint in a Phase III clinical trial. The company will continue to evaluate the drug in a narrower patient population validated through biomarker identification. The news is part of *DCAT Value Chain Insights Pipeline News*. [Read More](#)

7. [Takeda Ends Plans for a Vaccine Launch in Japan Due to GSK Supply](#)

Decision

Takeda Pharmaceutical Company has cancelled its planned launch in Japan of Vaxem Hib, a conjugate vaccine, due to the discontinuation of the manufacture and supply of the vaccine worldwide by GlaxoSmithKline (GSK). GSK is the sole supplier of the vaccine. [Read More](#)

8. Sorrento Expands ADC Manufacturing in China

Levena Biopharma, a subsidiary of San Diego-based Sorrento Therapeutics, has completed construction and put into operation a 25,000-square-foot manufacturing facility in Suzhou, China to support Sorrento's antibody drug conjugate (ADC) pipeline and services business. [Read More](#)

9. Pfizer, Sangamo Partner in Gene Therapy in a Deal Worth Up to \$545 Million

Pfizer has formed an exclusive, global collaboration and license agreement, worth up to \$545 million, with Sangamo Therapeutics for the development and commercialization of gene-therapy programs for hemophilia A, marking the third recent move for Pfizer in gene therapy. [Read More](#)

10. Sanofi Signs Pact For Artificial Intelligence in Drug Development

Sanofi has formed a strategic research collaboration and license option agreement, worth up to \$272 million, for bispecific small molecules to treat metabolic diseases with Exscientia, a drug-discovery company using artificial intelligence for drug discovery and design. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org